Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics director buys 100,000 shares on-market

This follows chairman Geoff Starr’s on-market share purchases last month.
dog with cannabis leaf
The company is focused on medicinal cannabis treatments for dogs and cats

CannPal Animal Therapeutics Ltd (ASX:CP1) non-executive director Robert Johnston has purchased 100,000 shares through on-market trades.

The purchase amounted to $11,911.86 and increased Johnston’s total holding in the company to 300,000 shares.

READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

CannPal intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.

The company's lead drug candidate is a cannabis-derived canine pain and inflammation medication.

Last month, CannPal received two key ethics approvals to progress the research and development of its lead therapeutic products, CPAT-01 and DermaCann.

CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.

CannPal hopes to complete recruitment for both studies by mid CY2019.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

Related Articles

cannabis plan in sun
February 21 2019
The cannabis company will manufacture, infuse and package branded recreational and wellness products
RYAH is the first cannabis vaporizer that lets users precisely regulate dose and temperature
cannabis plant
May 05 2019
The cannabis company invests in income-producing property and provides financing solutions and capital investment to service the blossoming cannabis industry
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use